Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 14
1992 15
1993 10
1994 18
1995 31
1996 19
1997 32
1998 25
1999 27
2000 33
2001 25
2002 19
2003 22
2004 21
2005 22
2006 21
2007 17
2008 6
2009 14
2010 15
2011 16
2012 17
2013 19
2014 13
2015 10
2016 8
2017 10
2018 7
2019 8
2020 4
2021 4
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

501 results
Results by year
Filters applied: . Clear all
Page 1
Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine.
Maghbooli M, Golipour F, Moghimi Esfandabadi A, Yousefi M. Maghbooli M, et al. Phytother Res. 2014 Mar;28(3):412-5. doi: 10.1002/ptr.4996. Epub 2013 May 9. Phytother Res. 2014. PMID: 23657930 Clinical Trial.
Two hours after using either drug, mean headaches severity decreased significantly. Efficacy of ginger powder and sumatriptan was similar. Clinical adverse effects of ginger powder were less than sumatriptan. ...The effectiveness of ginger powder in the treatment of …
Two hours after using either drug, mean headaches severity decreased significantly. Efficacy of ginger powder and sumatriptan was sim …
Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.
Boinpally R, Jakate A, Butler M, Periclou A. Boinpally R, et al. Pain Manag. 2022 May;12(4):499-508. doi: 10.2217/pmt-2021-0073. Epub 2021 Dec 13. Pain Manag. 2022. PMID: 34898273 Free article. Clinical Trial.
Results: Atogepant GMRs for AUC(0-t) and AUC(0-) versus with sumatriptan were within 90% CI 0.80-1.25, indicating no interaction; atogepant C(max) was reduced by 22% (GMR: 0.78; 90% CI: 0.69-0.89) with sumatriptan. ...Conclusion: Atogepant with sumatriptan ha …
Results: Atogepant GMRs for AUC(0-t) and AUC(0-) versus with sumatriptan were within 90% CI 0.80-1.25, indicating no interaction; ato …
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial.
Wienholtz NKF, Christensen CE, Zhang DG, Coskun H, Ghanizada H, Al-Karagholi MA, Hannibal J, Egeberg A, Thyssen JP, Ashina M. Wienholtz NKF, et al. Cephalalgia. 2021 May;41(6):731-748. doi: 10.1177/0333102420975395. Epub 2021 Feb 10. Cephalalgia. 2021. PMID: 33567890 Clinical Trial.
Of the 26 patients, four (15%) developed a PACAP38-induced migraine attack on sumatriptan and 11 patients (42%) on placebo (p = 0.016). There were no differences in area under the curve for headache intensity between sumatriptan (mean AUC 532) and placebo (mean AUC …
Of the 26 patients, four (15%) developed a PACAP38-induced migraine attack on sumatriptan and 11 patients (42%) on placebo (p = 0.016 …
Sumatriptan prevents central sensitization specifically in the trigeminal dermatome in humans.
Peng KP, Jürgens T, Basedau H, Ortlieb L, May A. Peng KP, et al. Eur J Pain. 2022 Nov;26(10):2152-2161. doi: 10.1002/ejp.2027. Epub 2022 Sep 14. Eur J Pain. 2022. PMID: 36001070 Clinical Trial.
RESULTS: After capsaicin application, primary hyperalgesia developed in both the sumatriptan and placebo groups in both dermatomes. However, sumatriptan exclusively prevented secondary hyperalgesia in the V1 dermatome but not on the forearm. Placebo exerted no effec …
RESULTS: After capsaicin application, primary hyperalgesia developed in both the sumatriptan and placebo groups in both dermatomes. H …
Sumatriptan.
Kaube H, May A, Pfaffenrath V. Kaube H, et al. BMJ. 1994 Jun 11;308(6943):1573-4. doi: 10.1136/bmj.308.6943.1573d. BMJ. 1994. PMID: 8019338 Free PMC article. Clinical Trial. No abstract available.
Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
Lipton RB, McGinley JS, Shulman KJ, Wirth RJ, Buse DC. Lipton RB, et al. Headache. 2017 Nov;57(10):1570-1582. doi: 10.1111/head.13165. Epub 2017 Sep 7. Headache. 2017. PMID: 28880380 Clinical Trial.
AVP-825 (ONZETRA() Xsail() ) is a delivery system containing 22 mg sumatriptan powder that uses a patient's own breath to deliver medication intranasally, targeting the upper posterior nasal cavity beyond the narrow nasal valve, an area lined with vascular mucosa co …
AVP-825 (ONZETRA() Xsail() ) is a delivery system containing 22 mg sumatriptan powder that uses a patient's own breath to deli …
Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.
Ferrari A, Pinetti D, Bertolini A, Coccia C, Sternieri E. Ferrari A, et al. Eur J Clin Pharmacol. 2008 May;64(5):489-95. doi: 10.1007/s00228-007-0443-9. Epub 2008 Jan 8. Eur J Clin Pharmacol. 2008. PMID: 18180912 Clinical Trial.
METHODS: We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and gender-matched groups: ten subjects (group A) with satisfactory response and ten (group B) with unsatisfactory response to oral sumatripta …
METHODS: We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and g …
Sumatriptan for prevention of acute mountain sickness: randomized clinical trial.
Jafarian S, Gorouhi F, Salimi S, Lotfi J. Jafarian S, et al. Ann Neurol. 2007 Sep;62(3):273-7. doi: 10.1002/ana.21162. Ann Neurol. 2007. PMID: 17557349 Clinical Trial.
RESULTS: Based on intention-to-treat analysis, AMS was more prevalent in placebo group (n = 23 [45.1%]) than sumatriptan group (n = 12 [23.5%]; p = 0.02). Headache also had a greater rate for placebo users (placebo vs sumatriptan group: 29 [56.9%] vs 17 [33.3%]; p = …
RESULTS: Based on intention-to-treat analysis, AMS was more prevalent in placebo group (n = 23 [45.1%]) than sumatriptan group (n = 1 …
A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
Gallagher RM, Dennish G, Spierings EL, Chitra R. Gallagher RM, et al. Headache. 2000 Feb;40(2):119-28. doi: 10.1046/j.1526-4610.2000.00017.x. Headache. 2000. PMID: 10759911 Clinical Trial.
RESULTS: A headache response at 2 hours was noted in 67.1% of patients taking zolmitriptan, 2.5 mg, and 64.8% of those taking zolmitriptan, 5 mg, versus 59.6% of patients taking sumatriptan, 25 mg, and 63.8% of those taking sumatriptan, 50 mg. At 2 and 4 hours, the …
RESULTS: A headache response at 2 hours was noted in 67.1% of patients taking zolmitriptan, 2.5 mg, and 64.8% of those taking zolmitriptan, …
Promethazine plus sumatriptan in the treatment of migraine: a randomized clinical trial.
Asadollahi S, Heidari K, Vafaee R, Forouzanfar MM, Amini A, Shahrami A. Asadollahi S, et al. Headache. 2014 Jan;54(1):94-108. doi: 10.1111/head.12259. Epub 2013 Nov 1. Headache. 2014. PMID: 24182419 Clinical Trial.
OBJECTIVE: This study was performed to evaluate the efficacy and safety of the combination of sumatriptan (50 mg) plus promethazine (SPr) (25 mg) compared with sumatriptan (50 mg) plus placebo in patients with migraine attacks. ...The 242 patients meeting the eligib …
OBJECTIVE: This study was performed to evaluate the efficacy and safety of the combination of sumatriptan (50 mg) plus promethazine ( …
501 results